<DOC>
	<DOCNO>NCT00006107</DOCNO>
	<brief_summary>Phase I trial study effectiveness docetaxel plus radiation therapy treat patient stage III stage IV head neck cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy Treating Patients With Stage III Stage IV Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose docetaxel administer concurrent boost radiotherapy patient advance squamous cell carcinoma head neck previously treat induction chemotherapy . - Determine toxicity treatment regimen patient population . - Determine efficacy treatment regimen patient . OUTLINE : This dose escalation study docetaxel . Patients receive docetaxel IV 1 hour weekly 4 week . Patients also undergo hyperfractionated radiotherapy daily , 5 day week , 4 week follow radiotherapy alone twice daily 2 week . Upon completion chemoradiotherapy , patient achieve complete response induction chemotherapy undergo neck surgical dissection 4-12 week follow completion radiotherapy . Cohorts 3-5 patient receive escalate dos docetaxel maximum tolerate dose ( MTD ) reach . The MTD dose precede 2 3 2 5 patient experience dose limit toxicity . Additional patient treat MTD . Patients follow monthly 1 year , annually thereafter . PROJECTED ACCRUAL : A total 18-25 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patient Eligibility : Pathology : Histologic documentation squamous cell carcinoma head neck variant ( lymphoepithelioma , undifferentiated epidermoid carcinoma , etc. ) . Stage : Patients enter protocol initial induction therapy , , prior induction regimen , previously untreated Stage III IV ( MO ) SCCHN . Evaluable disease induction therapy require . Required Prior therapy : Patients enter protocol receive platinum/FUra base induction chemotherapy . They may receive taxane part plan . Patients treated induction eligible provide receive three cycle chemotherapy , least one cycle chemotherapy , less 7 week start last cycle induction therapy Other malignancy : Patients previous head neck cancer ineligible , except patient treat surgery sole modality &gt; 2 year prior study entry . Patients concurrent malignancy site , except limited basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix ineligible . Patients nonSCCHN malignancy within 3 year study entry , except curatively treat basal cell carcinoma squamous cell carcinoma skin carcinoma situ cervix ineligible . Other prior therapy : Patients previously treat radiotherapy SCCHN eligible . Patients treat form prior chemotherapy , induction therapy describe section 3.21 within last 5 year eligible . Hormonally treated patient eligible . Performance : Patients must meet following performance criterion : Performance status : ≤ 2 ( ECOG ) . Complete recovery previous diagnostic therapeutic procedure require . Nutritional status : Adequate nutritionally balance enteral intake ≤ 1,800 kcal/day ) . Patients require intravenous alimentation primary source calorie exclude study . Patients persistent diarrhea ineligible . A PEG require prior initiation radiation . Life expectancy : Longer 3 month . Women child bear potential must pregnant history lactating time entry protocol men woman child bear potential must request use accept effective method birth control therapy . Organ Function : Biochemical hematological parameter ( obtain within 2 week study entry ) follow : Hepatic : SGOT &lt; 1.5 x ULN Alkaline Phosphatase &lt; 2.5 x ULN entry . Total Bilirubin = WNL SGOT must ≤ 2 x ULN isolate value . SGPT ≤ 2.5 x ULN Hematologic : WBC≥ 3,000/mm3 normal absolute neutrophil count ( ANC ) ≥ 1000 ; Platelet count ≥ 100,000/mm3 Hemoglobin ≥ 10 gm/d1 ( transfusion bring hemoglobin level permit clinically indicate , however , transfusion use solely order meet eligibility criterion ) . Neurologic : Peripheral neuropathy etiology must exceed grade 2 . Cardiovascular/Pulmonary : No acute cardiac dysrhythmias unstable cardiac condition angina . Other : Lack serious illness medical condition . Informed consent : Patients must give write informed consent . Followup : All patient must available monthly evaluation restaging physician Head Neck Cancer Clinic therapy . Patients history severe hypersensitivity reaction Taxotere drug formulate polysorbate 80 exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
</DOC>